Assertio Therapeutics (ASRT) Tops Q2 EPS by 1c

Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.19, $0.01 better than the analyst estimate of $0.18. Revenue for the quarter came in at $40.1 million versus the consensus estimate of $39.83 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Dick's Sporting Goods: Analyst sees long-term upside outweighing near-term noise
• Heron Therapeutics (HRTX) Misses Q2 EPS by 2c
• OPAL Fuels Inc. (OPAL) Misses Q2 EPS by 3c